

Famotidine Augmentation in Schizophrenia: Hope or Hype?

Chittaranjan Andrade, MD



Each month in his online column, Dr Andrade offers practical knowledge, ideas, and tips in psychopharmacology to JCP readers in psychiatric and general medical settings.

Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India (candrade@psychiatrist.com).

J Clin Psychiatry 2013;74(9):e855–e858
(doi:10.4088/JCP.13f08707)

© Copyright 2013 Physicians Postgraduate Press, Inc.

Antipsychotic medication does not always result in the remission of positive symptoms in patients with schizophrenia. Furthermore, in many patients in whom positive symptoms substantially or completely remit, negative symptoms, cognitive disturbances, and other impairments often remain. Antipsychotic augmentation is one of many strategies to which clinicians turn in an attempt to reduce the burden of these residual symptoms, and famotidine is one of many unconventional augmentation agents that has been studied in this context.

Histamine mechanisms may play a role in schizophrenia.^{1,2} Famotidine is a potent, selective histamine H₂ receptor antagonist that poorly penetrates the blood-brain barrier.^{3,4} Although H₂ receptors are present in the brain, there does not seem to be a strong argument made for the involvement of the H₂ receptor in schizophrenia; nevertheless, many case reports and small open studies suggest that famotidine may improve outcomes in patients with schizophrenia.

Famotidine Augmentation in Schizophrenia: Case Reports and Open Studies

Interest in the field began serendipitously when Kaminsky et al⁵ reported a patient who was treated with famotidine monotherapy (40 mg/d) for peptic ulcer disease. This patient also had schizophrenia, and the deficit symptoms that were present improved after the initiation of famotidine, worsened when famotidine was withdrawn, and improved again when famotidine was reintroduced. Rosse et al⁶ reported that a treatment-resistant patient with chronic undifferentiated schizophrenia also improved dramatically with famotidine (40–100 mg/d) across 10 months of treatment.

In an open-label study,⁷ famotidine (40 mg/d) was added to the current antipsychotic regimen of 10 schizophrenia and schizoaffective disorder patients who had responded poorly to drugs. There was a small but statistically significant improvement during famotidine treatment relative to before treatment and after treatment withdrawal. In another open-label study, Whiteford et al⁸ administered famotidine (40 mg/d) to 5 patients with chronic schizophrenia. Only 1 of 4 study completers showed improvement. Famotidine did not influence the levels of the concurrent antipsychotic medications.

In a study⁹ of 12 treatment-resistant schizophrenia patients, all of whom had significant negative symptoms, famotidine augmentation in the dose of 40 mg/d for 6 weeks or longer resulted in sufficient improvement in negative symptoms for 7 patients to be discharged; benefits were observed within 2–3 weeks of the onset of treatment. Rosenberg et al¹⁰ also reported improvement with famotidine (100 mg/d) after just 3 weeks of augmentation therapy in 19 patients with schizophrenia. Rosse et al¹¹ administered famotidine (100 mg/d) to 18 patients with schizophrenia or schizoaffective disorder; ongoing neuroleptic medications were continued. After 3 weeks of treatment, there were significant improvements in negative symptoms and overall psychopathology, as well as global ratings. Dannon et al¹² also reported improvement with famotidine augmentation of neuroleptic drugs in 11 schizophrenia patients who received treatment for 4 weeks.

- Famotidine is a potent, selective histamine H₂ receptor antagonist that has been investigated as an antipsychotic augmentation agent in treatment-refractory schizophrenia, especially for negative symptoms.
- Case reports, open studies, and small randomized controlled trials of famotidine have documented differing improvements in total ratings of psychosis, negative symptoms, general psychopathology, and other measures.
- Encouraging results notwithstanding, for theoretical reasons as well as for reasons related to the quality of the evidence, it is premature to seriously consider famotidine as a possible antipsychotic augmentation agent.

In all reports and studies, famotidine was generally well tolerated. There were, however, a few exceptions. For example, Whiteford et al⁸ reported that 1 patient had to be withdrawn because of new-onset aggression.

Famotidine Augmentation in Schizophrenia: Randomized Controlled Trials

Four small randomized controlled trials (RCTs) of famotidine augmentation in schizophrenia have been conducted. Abhari and Mohtasham¹³ randomized 38 chronic schizophrenia patients to receive famotidine (40 mg/d) or placebo for 6 weeks. All patients also received haloperidol (20 mg/d). Positive and Negative Syndrome Scale (PANSS) total scores decreased significantly more with famotidine than with placebo, but there was no significant difference in negative symptom outcomes. The full text of this study could not be evaluated because it was not in English.

In the only study of patients who were not medication-refractory, Poyurovsky et al¹⁴ described a 6-week RCT of famotidine (40 mg/d) versus placebo in 14 olanzapine-treated patients with first-episode schizophrenia. Famotidine did not attenuate olanzapine-related weight gain, nor did it influence treatment response to olanzapine on measures of positive symptoms, negative symptoms, or global severity of illness.

Farzin et al¹⁵ recruited 30 schizophrenia patients who had not responded to at least 2 previous antipsychotic trials. These patients were randomized to receive famotidine (60 mg/d) or placebo for 6 weeks. All patients also received perphenazine (40 mg/d). At the end of the study, mean PANSS total scores dropped by 49% (from 133 to 68) in famotidine-treated patients and by 22% (from 118 to 92) in placebo patients. The advantage for famotidine was also significant for the PANSS general psychopathology measure and for a measure of aggression. Results for other outcomes were not presented and were presumably not significant.

Famotidine was well tolerated in these RCTs, as far as could be judged from the limited adverse effect data that were provided.

A Recent RCT

A very recent RCT² received wide publicity in the scientific as well as lay press. The study was a small, 4-week, investigator-initiated trial in which 30 patients with chronic schizophrenia were randomized to receive famotidine (n = 16; 100 mg twice daily) or placebo (n = 14) along with their ongoing antipsychotic medication. The dose of famotidine was carefully chosen on the basis of its known pharmacokinetics, so as to ensure a 50%–80% occupancy of H₂ receptors in the brain during most of the day.

All patients had shown unsatisfactory response to previous and current psychotropic medications, and all required assisted living. The mean age of the sample was about 52 years. The sample was 60% female. Some patients were receiving antipsychotic polytherapy, and 11 (37%) were receiving clozapine. The mean PANSS score was 77.6 at baseline. No patient dropped out after randomization.

After 4 weeks of treatment, the PANSS total score decreased significantly more with famotidine than with placebo (by 11% vs 1%, respectively). Improvement in PANSS general psychopathology and Clinical Global Impressions scale scores was also significantly greater with famotidine than with placebo; the advantage for famotidine over placebo was 13% and 11%, respectively. However, improvement in PANSS positive symptom, PANSS negative symptom, and Scale for Assessment of Negative Symptoms scores did not differ significantly between the 2 groups. Famotidine was well tolerated.

The findings of this study suggest that, in chronic, medication-refractory, positive symptom schizophrenia, 4 weeks of treatment with famotidine (200 mg/d) results in a small (10%) but statistically significant improvement in the overall severity of illness.

Synthesis and Critical Appraisal

Table 1 provides a synthesis of the literature on famotidine augmentation of antipsychotic drugs in patients with schizophrenia. A critical appraisal of this literature is presented in Table 2.

There are some additional matters to be considered. Authors who have studied famotidine augmentation have speculated that the benefits arise from H₂ receptor antagonism. This hypothesis is but natural, given that H₂ antagonism is the principal and possibly sole action of the drug. In support of the H₂ antagonism hypothesis is the recent finding that clozapine is a potent H₂ receptor inverse agonist.¹⁶ However, asenapine is a potent H₂ receptor antagonist,¹⁷ and, unlike clozapine, no especial therapeutic advantage for asenapine has so far been postulated in schizophrenia. Furthermore, tricyclic and nontricyclic antidepressant drugs both block H₂ receptors,¹⁸ which is why these drugs were found effective in peptic ulcer disease.^{19,20} Even alprazolam blocks H₂ receptors.²¹ Although these drugs may benefit some patients with schizophrenia, it is generally considered that mechanisms such as monoamine reuptake

Table 1. Summary of the Literature on Famotidine Augmentation of Antipsychotic Medication in Patients With Schizophrenia

1. Two case reports^{5,6} (pooled N = 2) and 6 small open studies⁷⁻¹² (pooled N = 75) indicated benefits with famotidine augmentation in antipsychotic-refractory schizophrenia.
2. The only randomized controlled trial (RCT) in nonrefractory patients¹⁴ found no benefits with famotidine augmentation.
3. Three RCTs on famotidine augmentation in refractory schizophrenia^{2,13,15} reported benefits on different outcome measures and to different extents (10%–27% superiority over placebo).
4. Famotidine was very well tolerated in all reports and studies.

Table 2. Critical Appraisal of the Literature on Famotidine Augmentation in Schizophrenia

1. Favorable outcomes in case reports and small open studies do not constitute evidence; they merely support a hypothesis that famotidine augmentation may benefit patients with refractory schizophrenia.
2. The sample size (N = 14) in the only randomized controlled trial (RCT) in nonrefractory patients¹⁴ was too small for the negative results of the study to be considered definitive.
3. Of the remaining 3 RCTs,^{2,13,15} all with results favoring famotidine augmentation in antipsychotic-refractory schizophrenia, 1¹³ could not be evaluated because the full text was not in English. One found that famotidine outperformed placebo by a large margin (27%),¹⁵ and 1 found that famotidine outperformed placebo by only a small margin (10%),² which falls well below the threshold of most definitions of treatment response even in refractory schizophrenia. Only 1 RCT² presented a sound statistical plan, and no RCT corrected for type I errors arising from multiple testing.
4. There was no consistency in the pattern of benefits, although this could be because all RCTs were underpowered. Whereas the anecdotal data and open studies provided an expectation that famotidine would benefit negative symptoms, no RCT found negative symptom improvement with famotidine to significantly exceed that with placebo. In general, the RCTs found that total psychosis ratings, general psychopathology, and/or global assessment scores improved.

inhibition or muscarinic receptor blockade (rather than H₂ receptor blockade) mediate their therapeutic action.

Further, given that antidepressant drugs cross the blood-brain barrier better than does famotidine, one would expect H₂ receptor blockade in the brain to be better with antidepressants than with famotidine (the subject, however, has not been formally studied); if so, given the demonstrated efficacy of antidepressant augmentation in schizophrenia,²² the possible role for famotidine augmentation stands diminished.

About a decade ago, 2 studies^{23,24} suggested lamotrigine as a possible antipsychotic augmentation agent in atypical antipsychotic- and clozapine-refractory schizophrenia. Whereas benefits were small in both studies, one may argue that in such refractory samples, even small benefits could represent a clinically meaningful reduction in illness burden. Hopes were, however, dashed when 2 large (N = 217 and N = 212), industry-driven RCTs found that lamotrigine augmentation was no better than placebo in schizophrenia patients with stable, residual psychotic symptoms.²⁵ One wonders whether the famotidine experience will follow the lamotrigine story.

However, if famotidine is indeed a safe and effective augmenting agent in antipsychotic-refractory schizophrenia, many questions remain to be answered. No famotidine RCT has extended beyond 6 weeks; do benefits with famotidine increase with continued therapy, or are they at least maintained in the intermediate term? Studies have examined doses as low as 40 mg/d and as high as 200 mg/d; what is the ideal dose of famotidine? Although the efficacy of famotidine for different outcome measures has been inconsistent, might a specific symptom cluster be famotidine-responsive? Is famotidine effective even in patients who are already receiving potent H₂ inverse agonists or antagonists such as clozapine and asenapine? What are the long-term safety and efficacy of the drug in schizophrenia?

For the moment, the safest conclusion is that the use of famotidine as an antipsychotic augmentation agent is emphatically experimental.

REFERENCES

1. Arrang JM. Histamine and schizophrenia. *Int Rev Neurobiol.* 2007;78:247–287.
2. Meskanen K, Ekelund H, Laitinen J, et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. *J Clin Psychopharmacol.* 2013;33(4):472–478.
3. Chremos AN. Clinical pharmacology of famotidine: a summary. *J Clin Gastroenterol.* 1987;9(suppl 2):7–12.
4. Langtry HD, Grant SM, Goa KL. Famotidine: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. *Drugs.* 1989;38(4):551–590.
5. Kaminsky R, Moriarty TM, Bodine J, et al. Effect of famotidine on deficit symptoms of schizophrenia. *Lancet.* 1990;335(8701):1351–1352.
6. Rosse RB, Kendrick K, Tsui LC, et al. Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. *Clin Neuropharmacol.* 1995;18(4):369–374.
7. Deutsch SI, Rosse RB, Kendrick KA, et al. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. *Clin Neuropharmacol.* 1993;16(6):518–524.
8. Whiteford HA, Stedman TJ, McGrath JJ, et al. An open-label study of famotidine as a treatment for schizophrenia. *J Psychiatry Neurosci.* 1995;20(3):239–240.
9. Oyewumi LK, Vollick D, Merskey H, et al. Famotidine as an adjunct treatment of resistant schizophrenia. *J Psychiatry Neurosci.* 1994;19(2):145–150.
10. Rosenberg PB, Rosse RB, Johri SK, et al. Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report. *Clin Neuropharmacol.* 1996;19(3):276–281.
11. Rosse RB, Kendrick K, Fay-McCarthy M, et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. *Clin Neuropharmacol.* 1996;19(4):341–348.
12. Dannon P, Lepkifker E, Iancu I, et al. Famotidine: a supplemental drug for the treatment of schizophrenia. *Eur Psychiatry.* 1997;12(5):263–264.
13. Abhari SAA, Mohtasham S. Clinical trial of H₂ blocker: augmentation treatment of schizophrenia. *Andeesheh va Rajfar.* 2000;5(3):10–17.
14. Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. *Eur Neuropsychopharmacol.* 2004;14(4):332–336.
15. Farzin D, Hosseini SH, Shafaat A. A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia. *Iran J Med Sci.* 2005;30(2):59–62.
16. Humbert-Claude M, Davenas E, Gbahou F, et al. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. *Psychopharmacology (Berl).* 2012;220(1):225–241.
17. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. *J Psychopharmacol.* 2009;23(1):65–73.

18. Alvarez FJ, Casas E, Franganillo A, et al. Effects of antidepressants on histamine H₂ receptors in rat isolated uterus. *J Pharmacol*. 1986;17(3):351–354.
19. Goodman WK, Charney DS. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. *J Clin Psychiatry*. 1985;46(10 pt 2):6–24.
20. Orsulak PJ, Waller D. Antidepressant drugs: additional clinical uses. *J Fam Pract*. 1989;28(2):209–216.
21. Alvarez FJ, Velasco A, Palomares JL. Blockade of muscarinic, histamine H₁ and histamine H₂ receptors by antidepressants. *Pharmacology*. 1988;37(4):225–231.
22. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia [published online ahead of print July 3, 2013]. *Int J Neuropsychopharmacol*. 2013;1–12.
23. Tiihonen J, Hallikainen T, Rynnänen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. *Biol Psychiatry*. 2003;54(11):1241–1248.
24. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. *Biol Psychiatry*. 2004;56(6):441–446.
25. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. *J Clin Psychopharmacol*. 2007;27(6):582–589.

JOIN THE ONLINE DISCUSSION of this article at
PSYCHIATRIST.COM Enter Keyword